Skip to main content

Research Repository

Advanced Search

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Collett, Laura; Howard, Dena R.; Munir, Talha; McParland, Lucy; Oughton, Jamie B.; Rawstron, Andy C.; Hockaday, Anna; Dimbleby, Claire; Phillips, David; McMahon, Kathryn; Hulme, Claire; Allsup, David; Bloor, Adrian; Hillmen, Peter

Authors

Laura Collett

Dena R. Howard

Talha Munir

Lucy McParland

Jamie B. Oughton

Andy C. Rawstron

Anna Hockaday

Claire Dimbleby

David Phillips

Kathryn McMahon

Claire Hulme

Profile Image

Dr David Allsup D.J.Allsup@hull.ac.uk
Senior Lecturer in Haematology and Honorary Consultant

Adrian Bloor

Peter Hillmen



Abstract

Background
Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and require further therapy, and so new, effective, targeted therapies that improve remission rates, reduce relapses, and have fewer side effects, are required. The FLAIR trial will assess whether ibrutinib plus rituximab (IR) is superior to FCR in terms of progression-free survival (PFS).

Methods/design
FLAIR is a phase III, multicentre, randomised, controlled, open, parallel-group trial in patients with previously untreated CLL. A total of 754 participants will be randomised on a 1:1 basis to receive standard therapy with FCR or IR. Participants randomised to FCR will receive a maximum of six 28-day treatment cycles. Participants randomised to IR will receive six 28-day cycles of rituximab, and ibrutinib taken daily for 6 years until minimal residual disease (MRD) negativity has been recorded for the same amount of time as it took to become MRD negative, or until disease progression. The primary endpoint is PFS according to the International Workshop on CLL (IWCLL) criteria. Secondary endpoints include: overall survival; proportion of participants with undetectable MRD; response to therapy by IWCLL criteria; safety and toxicity; health-related quality of life (QoL); and cost-effectiveness.

Discussion
The trial aims to provide evidence for the future first-line treatment of CLL patients by assessing whether IR is superior to FCR in terms of PFS, and whether toxicity rates are favourable.

Trial registration
ISRCTN01844152. Registered on 8 August 2014, EudraCT number 2013-001944-76. Registered on 26 April 2013.

Citation

Collett, L., Howard, D. R., Munir, T., McParland, L., Oughton, J. B., Rawstron, A. C., …Hillmen, P. (2017). Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18(1), Article 387. https://doi.org/10.1186/s13063-017-2138-6

Journal Article Type Article
Acceptance Date Nov 3, 2016
Online Publication Date Aug 22, 2017
Publication Date Aug 22, 2017
Deposit Date Mar 22, 2018
Publicly Available Date Mar 29, 2024
Journal Trials
Print ISSN 1745-6215
Electronic ISSN 1745-6215
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 18
Issue 1
Article Number 387
DOI https://doi.org/10.1186/s13063-017-2138-6
Keywords Medicine (miscellaneous); Pharmacology (medical)
Public URL https://hull-repository.worktribe.com/output/752047
Publisher URL https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-2138-6

Files

Article (1.2 Mb)
PDF

Copyright Statement
© The Author(s). 2017

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.





You might also like



Downloadable Citations